Drug Profile
Metastatin
Latest Information Update: 22 Dec 2004
Price :
$50
*
At a glance
- Originator EntreMed
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Dec 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 29 Apr 2003 EntreMed is set to close a $US10.25 million equity deal to support development of several of its programmes
- 14 Nov 2002 Suspended - Preclinical for Cancer in USA (unspecified route)